5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)

The goal of highly active antiretroviral therapy (HAART) is to suppress HIV RNA to undetectable levels over many years and is primarily dependent on adherence, which is aided by using a once daily regimen with good tolerability and low pill burden. In Study 934 the time to discontinuation for the twice daily regimen of EFV qd + zidovudine/lamivudine bid was significantly shorter than for the once daily regimen (EFV+FTC+TDF) (p=0.003). Herein are the 5 year safety and efficacy data for this once daily regimen. Supplement: Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection http://www.biomedcentral.com/content/pdf/1758-2652-13-S4-info.pdf Conference: Tenth International Congress on Drug Therapy in HIV Infection 7-11 November 2010 Glasgow, UK (Published: 8 November 2010) doi:10.1186/1758-2652-13-S4-P6 Cite this article as: Lazzarin et al.: 5-year safety and efficacy of the oncedaily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/ tenofovir disoproxil fumarate (TDF). Journal of the International AIDS Society 2010 13(Suppl 4):P6. Full text: PubMed Central: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113064/